Xenetic Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary
19/03/2025 21:00
Xenetic Biosciences Inc XBIO.OQ reported a quarterly adjusted loss of 68 cents per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -77 cents. The lone analyst forecast for the quarter was for a loss of 20 cents per share. Revenue fell 3.6% to $648.00 thousand from a year ago; analysts expected $230.00 thousand. Xenetic Biosciences Inc's reported EPS for the quarter was a loss of 68 cents. The company reported a quarterly loss of $1.05 million. Xenetic Biosciences Inc shares had fallen by 13.3% this quarter. FORECAST CHANGES The mean earnings estimate of analysts was unchanged in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold" This summary was machine generated from LSEG data March 19 at 09:00 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | -0.20 | -0.68 | Missed |
| Sep. 30 2024 | -0.14 | -0.28 | Missed |
| Jun. 30 2024 | -0.83 | -0.83 | Met |
| Mar. 31 2024 | -0.79 | -0.78 | Beat |